# EDGAR Filing Document

**Accession Number:** 0001795579
**File Stem:** 0001104659-23-008650
**Filing Date:** 2023-1
**Character Count:** 4951
**Document Hash:** 2f83160406e8205e6e48f25bb0a60856
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-008650.hdr.sgml**: 20230131

**ACCESSION NUMBER**: 0001104659-23-008650

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230131

**FILED AS OF DATE**: 20230131

**DATE AS OF CHANGE**: 20230131

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Calliditas Therapeutics AB
- **CENTRAL INDEX KEY:** 0001795579
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** V7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39308
- **FILM NUMBER:** 23573083

**BUSINESS ADDRESS:**
- **STREET 1:** KUNGSBRON 1, D5
- **CITY:** STOCKHOLM
- **STATE:** V7
- **ZIP:** SE-111 22
- **BUSINESS PHONE:** 46 8411 3005

**MAIL ADDRESS:**
- **STREET 1:** KUNGSBRON 1, D5
- **CITY:** STOCKHOLM
- **STATE:** V7
- **ZIP:** SE-111 22

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report: January 31, 2023**

**(Commission File No. 001-39308)**

**CALLIDITAS THERAPEUTICS AB**

**(Translation of registrant's name into English)**

**Kungsbron 1, D5<br> SE-111 22<br> Stockholm, Sweden<br> (Address of registrant's principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

 

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

Enclosed hereto is a copy of an announcement published by Calliditas Therapeutics AB on January 31, 2023.

The information contained in this Form 6-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [99.1](tm235038d1_ex99-1.htm) | &nbsp;&nbsp;&nbsp;[Press Release dated January 31, 2023.](tm235038d1_ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CALLIDITAS THERAPEUTICS AB** | **CALLIDITAS THERAPEUTICS AB** |
| Date: January 31, 2023 | By: | /s/ Fredrik Johansson |
|  |  | Fredrik Johansson<br> Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](image_001.jpg)

---

| | |
|:---|:---|
| **Stockholm, Sweden** | **January 31, 2023** |

---

<br> Number of shares and votes in Calliditas Therapeutics

During January, Calliditas Therapeutics AB (publ) has issued 7,500 common shares connected to the company's long term incentive program 2019/2022. Thus, as of January 31, 2023, the number of shares and votes in the company amounts to 59,580,087 shares and 59,580,087 votes.

**For further information, please contact:**

Mikael Widell, Investor relations

Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com

*The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on January 31, 2023.* 

**About Calliditas**

Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product, developed under the name Nefecon, has been granted accelerated approval by the FDA under the trade name TARPEYO® and conditional marketing authorization by the European Commission under the trade name Kinpeygo®. Additionally, Calliditas is conducting a Phase 2b/3 clinical trial in primary biliary cholangitis and a Phase 2 proof-of-concept trial in head and neck cancer with its NOX inhibitor product candidate, setanaxib. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).